Saturday 17 October 2026
Export CNSP’s income statement to Excel — free account
CNS Pharmaceuticals, Inc.
CNSP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 94.1% and free cash flow grew 33.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.85
0.33
−6.37%
Follow CNSP
CNS Pharmaceuticals, Inc. (CNSP) P/E ratio
CNS Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (May 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
89
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| KPTI Karyopharm Therapeutics Inc. compare | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| SNTI Senti Biosciences, Inc. compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. | n/m |
| SNGX Soligenix Inc. compare | n/m |
| XTLB XTL Biopharmaceuticals Ltd. compare | n/m |
| CURX Curanex Pharmaceuticals Inc compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)